Nurix Therapeutics Reports Third Quarter Fiscal 2024 Financial Results and Provides a Corporate Update

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. META
3. ABBV
4. SPY
5. MU
6. FDX
7. IBM
8. PRIM
9. PFE
10. AWK

Go back to Nurix Therapeutics Reports Third Quarter Fiscal 2024 Financial Results and Provides a Corporate Update

Wells Fargo Reiterates Overweight Rating on Nurix (NRIX)

October 15, 2024 6:19 AM EDT

Wells Fargo analyst Derek Archila reiterated an Overweight rating and $32.00 price target on Nurix (NASDAQ: NRIX)

The analyst comments "Thoughts on the stock. Shares are up +146% vs XBI's +10% YTD. While there is decent value priced in for NX-5948's oppty... More